Pipeline
Pipeline
Rooted in LCB's innovative platform technologies, LCB is building a robust discovery and development ADC and small molecule pipeline, focusing on therapies that will address significant unmet medical needs in anticancer, antibiotics, anticoagulant and antifibrotics.
Our Pipeline
ADC
LCB has leveraged over forty years of industry learnings to develop proprietary platform technologies (ConjuAll) of conjugation, linker that enable us to design antibody drug conjugates (ADCs) with improved efficacy, safety and tolerability compared to existing ADC drugs.
Coupled with LCB’s proprietary payloads, we are assembling a robust pipeline of innovative ADC programs in collaboration with global partners.
Coupled with LCB’s proprietary payloads, we are assembling a robust pipeline of innovative ADC programs in collaboration with global partners.
Program
Indication
Antibody provider
Licensees
Stage
Discovery
Preclinical
Clinical stage
Notes
ADC Products
LCB14
HER2-MMAF
BC,GC,OC,UC
Antibody provider
Licensees
Clinical stage
- L/O for China
- Phase I for Breast cancer
- Phase I for Breast cancer
Licensees
Clinical stage
- Phase II for NSCLC
Licensees
Clinical stage
- Phase II for Multi solid cancers
Licensees
Clinical stage
- Phase II for CRC
Licensees
Clinical stage
- Phase II for Gastric
Licensees
Clinical stage
- Phase II for Gastric (PD-L1 combination)
Licensees
Clinical stage
- Phase III for Breast cancer (vs T-DM1)
Licensees
Clinical stage
- L/O for World wide(ex China)
LCB84
TROP2-MMAE
Solid, Heme
Antibody provider
Licensees
Clinical stage
LCB71
ROR1-pPBD
CLL, MCL ,ALL, TNBC, NSCLC, Solid
Antibody provider
Licensees
Clinical stage
LCB73
CD19-pPBD
ALL, NHL, CLL, DLBCL
Antibody provider
Licensees
Preclinical
LCB97
Solid
Antibody provider
Licensees
Discovery
LCB02A
Solid, Heme
Antibody provider
Licensees
Discovery
LCB41A
B7-H4
Solid,Heme
Antibody provider
Licensees
Discovery
LCB67
DLK1-MMAE
SCLC, HCC, NB, RD, MDS, AML
Antibody provider
Licensees
Discovery
ADC Platform
LCB85
Solid, Heme
Antibody provider
Licensees
Discovery
LCB20A
Antibody provider
Licensees
Discovery
LCB42A
undisclosed
Antibody provider
Licensees
Discovery